A comparison of the effectiveness of intralesional tranexamic acid against platelet-rich plasma in the treatment of melasma

Authors

  • Manasha Karthikeyan Department of Dermatology, Sri. Lakshmi Narayana Institute of Medical Sciences, Villianur Commune, Agaram, Kudappakkam, Puducherry, India
  • Govardhan Jagadeesh Kumar Department of Dermatology, Sri. Lakshmi Narayana Institute of Medical Sciences, Villianur Commune, Agaram, Kudappakkam, Puducherry, India
  • Indradevi Radhakrishnan Department of Dermatology, Sri. Lakshmi Narayana Institute of Medical Sciences, Villianur Commune, Agaram, Kudappakkam, Puducherry, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20240970

Keywords:

Melasma, Tranexamic acid, PRP, MASI

Abstract

Background: Melasma, derived from the Greek word "melas" meaning "black", manifests as an acquired, more or less symmetrical hypermelanosis of sun-exposed skin. This study aimed to compare and evaluate the efficacy and safety of intradermal injection of tranexamic acid and platelet-rich plasma in treating various types of melasma.

Methods: Conducted from June 2022 to December 2023 at the outpatient department of dermatology, Sri Lakshmi Narayana institute of medical sciences, Puducherry, this split-face prospective study involved 40 melasma cases. Tranexamic acid (4 mg/ml) was intradermally injected into the right side of the face, while PRP was injected into the left side. Improvement was assessed using the modified Melasma area severity index (MASI) grading system and dermoscopy, measuring disease severity and percentage of improvement before and after therapy on both sides of the face.

Results: The study comprised predominantly females (80%) aged 20 to 30 years (50%), followed by those aged 30 to 40 years (35%). Most cases (93%) exhibited a gradual onset, with centrofacial (52.5%) and malar (37.5%) patterns being predominant. Mixed pattern (67.5%) was common. Pre-treatment mean MASI scores for tranexamic acid and PRP sides were 7.54 and 6.92, respectively, with post-treatment scores of 4.6 and 2.83, respectively.

Conclusions: Intradermal PRP demonstrated significantly superior efficacy over intradermal tranexamic acid in managing melasma, particularly in the longer term. Thus, PRP, coupled with good compliance, may substantially reduce the disease burden compared to conventional tranexamic acid treatment.

Metrics

Metrics Loading ...

References

Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4(6):698-710.

Hexsel D, Rodrigues T, Dal’Forno T, Zechmeister‐Prado D, Lima MJ. Melasma and pregnancy in southern Brazil. Venereology. 2009;23:367-8.

Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131(12):1453-7.

Morelli JG, Norris DA. Influence of inflammatory mediators and cytokines on human melanocyte function. J Invest Dermatol. 1993;100(2):191S-5.

Jang Y, Lee J, Kang H, Lee ES, Kim Y. Oestrogen and progesterone receptor expression in melasma: an immunohistochemical analysis. Venereology. 2010; 24:1312-6.

Handel A, Lima P, Tonolli V, Miot L, Miot H. Risk factors for facial melasma in women: a case control study. Venereology. 2014;171:588-94.

Mumtaz M, Chandio TH, Shahzad MK, Hanif N, Anwar S, Rafique S. Comparing the Efficacy of Patelet-rich Plasma (PRP) versus Tranexamic Acid (4 mg/ml) as Intradermal Treatments of Melasma. J Coll Physicians Surg Pak. 2021;31(5):502-5.

Bentley-Phillips B, Bayles MA. Cutaneous reactions to topical application of hydroquinone. Results of a 6-year investigation. S Afr Med J. 1975;49(34):1391-5.

Hurley ME, Guevara IL, Gonzales RM, Pandya AG. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol. 2002;138(12):1578-82.

Li YH, Chen JZ, Wei HC, Wu Y, Liu M, Xu YY, Dong GH, Chen HD. Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients. Dermatol Surg. 2008;34(5):693-700.

Shimizu M, Naito T, Okano A, Aoyagi T. Trans-4-aminomethylcyclohexanecarboxylic acid as a potent antiplasmin agent. Chem Pharm Bull. 1965;13(8): 1012-4.

Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014;19(8):753-7.

Maeda K, Xing X, Xu Z, Chen L, Jin S, Zhang C, Xiang L. Tranexamic acid inhibits melanogenesis partially via stimulation of TGF-β1 expression in human epidermal keratinocytes. Exp Dermatol. 2022; 31(4):633-40.

Al-Shami SH. Treatment of periorbital hyperpigmentation using platelet-rich plasma injections. Am J Dermatol Venereol. 2014;3:87-94.

Alves R, Grimalt R. A Review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin Appendage Disord. 2018;4(1):18-24.

Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64(1):78-83.

Zhang X, Yang X, Yang H, Yang Y. Study of inhibitory effect of acidum tranexamicum on melanin synthesis. Chin J Dermatol. 2003;2:227-9.

Abd Elraouf IG, Obaid ZM, Fouda I. Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study. Arch Dermatol Res. 2023;315(6): 1763-1770.

Elraouf IG, Obaid ZM, Fouda I. Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study. Arch Dermatol Res. 2023;315(6):1763-70.

Serra M, Bohnert K, Narda M, Granger C, Sadick N. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging. J Drugs Dermatol. 2018;17(12):1310-5.

Jin Y, Jiang W, Yao Y, Huang H, Huang J. Clinical efficacy of laser combined with menstrual regulation in the treatment of female melasma: a retrospective study. Lasers Med Sci. 2019;34(6):1099-105.

Gharib K, Mostafa FF, Ghonemy S. Therapeutic effect of microneedling with platelet-rich plasma versus microneedling with tranexamic acid for melasma. Dermatology. 2021;14:44.

Tuknayat A, Bhalla M, Thami GP. Platelet-rich plasma is a promising therapy for melasma. J Cosmet Dermatol. 2021;20(8):2431-6.

Gamea MM, Kamal DA, Donia AA, Hegab DS. Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma. J Dermatolog Treat. 2022;33(2):798-804.

Zhang C, Wu T, Shen N. Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin. Pak J Med Sci. 2022; 38(8):2163-8.

Downloads

Published

2024-04-24

How to Cite

Karthikeyan, M., Kumar, G. J., & Radhakrishnan, I. (2024). A comparison of the effectiveness of intralesional tranexamic acid against platelet-rich plasma in the treatment of melasma. International Journal of Research in Dermatology, 10(3), 126–131. https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20240970

Issue

Section

Original Research Articles